Immunogenicity and safety of the bivalent HPV vaccine in female patients with juvenile idiopathic arthritis: A prospective controlled observational cohort study

Annals of the Rheumatic Diseases

Volumn 73, Issue 8, 2014, Pages 1500-1507

  Heijstek, Marloes W ^a   Scherpenisse, Mirte ^b,c   Groot, Noortje ^a   Tacke, Carline ^a   Schepp, Rutger M ^b   Buisman, Anne Marie ^b   Berbers, Guy A M ^b   Van Der Klis, Fiona R M ^b   Wulffraat, Nico M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE DURATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMORAL IMMUNITY; IMMUNOGENICITY; INJECTION SITE CONTUSION; INJECTION SITE ERYTHEMA; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MEMORY CELL; OBSERVATIONAL STUDY; PRIORITY JOURNAL;

ADOLESCENT; ANTIBODIES, VIRAL; ARTHRITIS, JUVENILE; CHILD; FEMALE; FOLLOW-UP STUDIES; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROSPECTIVE STUDIES; UTERINE CERVICAL NEOPLASMS;

EID: 84903905433     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203429     Document Type: Article

References (28)

1. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum 2002;46:2287-93.
2. Moxon ER, Siegrist CA. The next decade of vaccines: societal and scientific challenges. Lancet 2011;378:348-59.
3. Ravelli A, Martini A. Juvenile idiopathic arthritis. Lancet 2007;369:767-78.
4. Abinun M. An overview of infectious complications in children on new biologic response-modifying agents. Pediatric Health 2010;4:509-17.
5. De Carvalho N, Teixeira J, Roteli-Martins CM, et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010;28:6247-55.
6. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367:1247-55.
7. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369:2161-70. (Pubitemid 46977438)
8. Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis 2011;70:1704-12.
9. Petty RE, Southwood TR, Manners P, et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004;31:390-2. (Pubitemid 38160763)
10. Scherpenisse M, Mollers M, Schepp RM, et al. Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine 2012;30:6686-93.
11. Anttila M, Eskola J, Ahman H, et al. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J Infect Dis 1998;177:1614-21. (Pubitemid 28243587)
12. Buisman AM, de Rond CG, Ozturk K, et al. Long-term presence of memory B-cells specific for different vaccine components. Vaccine 2009;28:179-86.
13. Consolaro A, Ruperto N, Bazso A, et al. Development and validation of a composite disease activity score for juvenile idiopathic arthritis. Arthritis Rheum 2009;51:658-66.
14. Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997;40:1202-9. (Pubitemid 27430130)
15. Lehtinen M, Paavonen J, Wheeler CM, et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012;13:89-99.
16. Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. Vaccine 2009;27:581-7.
17. Kemp TJ, Safaeian M, Hildesheim A, et al. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix ((R)). Vaccine 2012;31:165-70.
18. Dauner JG, Pan Y, Hildesheim A, et al. Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010;28:5407-13.
19. Bernasconi NL, Traggiai E, Lanzavecchia A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 2002;298: 2199-202. (Pubitemid 35471246)
20. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006; 24:5937-49. (Pubitemid 44080367)
21. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009;5:705-19.
22. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011;7:1343-58.
23. Mayerl C, Prelog M. Immunosenescence and juvenile idiopathic arthritis. Autoimmun Rev 2012;11:297-300.
24. Brandt D, Gershwin ME. Common variable immune deficiency and autoimmunity. Autoimmun Rev 2006;5:465-70.
25. Heijstek MW, van Gageldonk PG, Berbers GA, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis 2012;71:948-54.
26. Wraith DC, Goldman M, Lambert PH. Vaccination and autoimmune disease: what is the evidence? Lancet 2003;362:1659-66. (Pubitemid 37443537)
27. Rondy M, van Lier A, van de Kassteele J, et al. Determinants for HPV vaccine uptake in the Netherlands: A multilevel study. Vaccine 2010;28:2070-5.
28. Klumb EM, Pinto AC, Jesus GR, et al. Are women with lupus at higher risk of HPV infection? Lupus 2010;19:1485-91.